Cryoablation Treats Cardiac Arrhythmias

The device, called SurgiFrost, has been cleared by the US Food and Drug Administration (FDA).

The SurgiFrost is a malleable, single-use cryosurgical probe used to ablate cardiac tissue while a patient is undergoing a primary cardiac surgical procedure, such as coronary artery bypass grafting (CABG) or mitral valve (MV) replacement or repair. According to CryoCath Technologies, Inc. (Montreal, Canada), which developed the SurgiFrost, it is now widely accepted that around 50% of patients undergoing MV surgery and up to 20% of those undergoing CABG have some form of arrhythmia. Surgeons believe it is appropriate to treat a patient's arrhythmia as a secondary outcome while the patient is being primarily treated for mitral valve disease or coronary vessel obstruction.

"Initial patients successfully treated with SurgiFrost in Sweden and Italy had procedure times ranging between 10 and 25 minutes. We believe these very encouraging European results are a promising indicator of a strong uptake of the product,” said Steven G. Arless, president and CEO of Cryocath.




Related Links:
CryoCath